Back to results
US 11,213,597 B2Granted
Kinin-based theranostic probes for solid cancers and uses thereof
AssigneeSociéTé De Commercialisation Des Produits De La Recherche AppliquéE Socpra Sciences Santé Et Humaines S.E.C.
InventorsFernand Gobeil, Brigitte Guerin, Martin Lepage, Robert Sabbagh, David Fortin
Life of this patent
Estimating the term…
Abstract
It is provided new chemical entities allowing simultaneous diagnosis and treatment of cancers. More specifically, it is provided a theranostic compound consisting of a stabilized peptide ligand (agonists and antagonists) for the kinin B1 receptors (B1R) conjugated to specific radionuclides (e.g. 64Cu) suitable for dual imaging/radiotherapy applications.
Claims2
A theranostic composition comprising a theranostic compound and a carrier, wherein the theranostic compound is:
- 64Cu-NOTHA2-βAla-Orn1-Arg2-Oic3-Pro4-Gly5-(αMe)Phe6-Ser7-DβNal8-Ile9-OH;
- 64Cu-NOTA-βAla-Orn1-Arg2-Oic3-Pro4-Gly5-(αMe)Phe6-Ser7-DβNal8-Ile9-OH;
- 64Cu-NOTA-Orn1-Arg2-Oic3-Pro4-Gly5-(αMe)Phe6-Ser7-DβNal8-Ile9-OH;
- 64Cu-NOTA-βAla-(L or D)Lys1-Arg2-Pro3-Hyp4-Gly5-Igl6-Ser7-Pro8-DPhe9-OH;
- 64Cu-NOTA-(L or D)Lys1-Arg2-Pro3-Hyp4-Gly5-Igl6-Ser7-Pro8-DPhe9-OH;
- 64Cu-NOTA-Lys1-Arg2-Oic3-Pro4-Gly5-(αMe)Phe6-Ser7-DβNal8-Ile9-OH;
- 64Cu-NOTA-βAla-Lys1-Arg2-Oic3-Pro4-Gly5-(αMe)Phe6-Ser7-DβNal8-Ile9-OH;
- 64Cu-NOTA-Arg1-Arg2-Oic3-Pro4-Gly5-(αMe)Phe6-Ser7-DβNal8-Ile9-OH;
- or
- 64Cu-NOTA-βAla-Arg1-Arg2-Oic3-Pro4-Gly5-(αMe)Phe6-Ser7-DβNal8-Ile9-OH.
7 more elements
Dependencies are inferred from the claim text.